BioSyent Posts 27% Revenue Growth in Q1 2026, Bolstered by Oral Science Acquisition
Event summary
- BioSyent reported Q1 2026 revenue of CAD 13.9M, up 27% YoY, driven by the March 2026 acquisition of Oral Science Inc.
- EBITDA rose 14% YoY to CAD 3.6M, with adjusted EBITDA up 22% excluding acquisition costs.
- Pharmaceutical sales grew 1% YoY to CAD 10.8M, while new Oral Health segment contributed CAD 3M in March.
- Company repurchased 100,000 shares and increased quarterly dividend by 10% to CAD 0.055 per share.
- Trailing twelve-month return on average equity held steady at 22%.
The big picture
BioSyent's Q1 2026 results highlight its strategic shift toward portfolio diversification through the Oral Science acquisition, adding a new revenue stream while maintaining strong profitability metrics. The company's ability to navigate geopolitical risks in its international pharmaceutical business will be key to sustaining growth. With a 20% YoY increase in trailing twelve-month revenue to CAD 46M, BioSyent is positioning itself as a consolidator in the specialty healthcare products space.
What we're watching
- Integration Risk
- How BioSyent will manage the operational integration of Oral Science and sustain its profitability contribution.
- Geopolitical Exposure
- Whether Middle East shipments of FeraMAX can maintain momentum despite ongoing regional conflicts.
- Portfolio Diversification
- The pace at which BioSyent can expand its Oral Health segment beyond the initial acquisition.
Related topics